Risk Factors for Acute Retinopathy of Prematurity

McNamara JA, Moreno R, Tasman WS. Retinopathy of prematurity. In: Tasman W, Jaeger EA, eds. Duane’s Clinical Ophthalmology. Vol. 3, Philadelphia: Lippincott-Raven, 1996. Ch. 10 Pierce EA, Petersen RA, Smith LE. Retinopathy of prematurity. In: Albert D, Jakoiec F, eds. Principles and Practice of Ophthalmology. Philadelphia: W.H. Saunders Co., 2000: pp. 4443–4460 Phleps DL. Vitamin E and retrolental fibroplasias in 1982. Pediatrics 1982;70:420–424 Al-Amro SA, Al-Kharfi TM, Thabit AA, et al. Retinopathy of prematurity at King Khaled University Hospital in Riyadh. Saudi Med J 2003;24:720–724 Hunter DG, Mukai S. Retinopathy of prematurity: Pathogenesis, diagnosis and treatment. Int Ophthalmol Clin 1992;32:163–184 Compbell PB, Bull MJ, Ellis FD. Incidence of retinopathy of prematurity in a tertiary newborn Intensive Care unit. Arch Ophthalmol 1983;101:1686–1688 Quinn GE, Johnson L, Abbasi S. Onset of retinopathy of prematurity as related to post natal and postconceptional age. Br J Ophthalmol 1992;76:284–288 Kinsey VE, Jacobus JT, Hemphill FM. Cooperative study of retrolental fibroplasia and the use of oxygen. Arch Ophthalmol 1956;56:481–529 Flyn JT, Bancalari E, Snyder SE. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992;326:1050–1054 Lucey JF, Dangman B. A reexamination of the role of oxygen in retrolental fibroplasias. Pediatrics 1984;73:82–96 Owens WC, Owens EU. Retrolental fibroplasia in premature infants: II. Studies on the prophylaxis of the disease: The use of alphatocopheryl acetate. Am J Ophthalmol 1949;32:497–505 Hittner HM, Godio LB, Rudolph AJ. Retrolental fibroplasia: Efficacy of vitamin E in a double-blind clinical study of preterm infants. N Engl J Med 1981;305:1365–1371 Finer NN, Grant G, Schindler RF. Effect of intramuscular vitamin E on frequency and severity of retrolental fibroplasia: a controlled trial. Lancet 1982;1:1087–1091 Johnson L, Quinn GE, Abbasi S, et al. Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: A controlled clinical trial. J Pediatr 1989;114:827–838 Puklin JE, Simon RM, Ehrenkranz RA. Influence on retrolental fibroplasia of intramuscular vitamin E administration during respiratory distress syndrome. Ophthalmology 1982;89:96–102 Milner RA, Bell E, Blanchette V. Vitamin E supplement in under 1,500 g neonates. Retinopathy of prematurity conference, December 4–6, 1981. Columbus, OH: Ross Laboratories, 1981;703–716 Phelps DL, Rosenbaum AL, Isenberg SJ. Tocopherol efficacy and safety for preventing retinopathy of prematurity: A randomized, controlled, double-masked trial. Pediatrics 1987;79:489–500 Committee of the Institute of Medicine. A report of a study - vitamin E, retinopathy of prematurity. IOM-86-02. Washington, DC: National Academy Press, 1986 Ehrenkranz RA. Vitamin E and retinopathy of prematurity: Still controversial. J Pediatr 1989;114:801–803 Brown DR, Biglan AW, Stretavsky MM. Retinopathy of prematurity: The relationship with intraventricular hemorrhage and bronchopulmonary dysplasia. J Pediatr Ophthalmol Strabismus 1990;27:268–271 Bassiouny MR. Risk factors associated with retinopathy of prematurity: A study from Oman. J Trop Pediatr 1996;42:355–358 Arroe M, Peitersen B. Retinopathy of prematurity: Review of a seven-year period in a Danish neonatal intensive care unit. Acta Paediatr 1994;83:501–505 Batton DG, Roberts C, Trese M. Severe retinopathy of prematurity and steroid exposure. Pediatrics 1992;90:534–536 Flower RW, Blake DA, Wajer SD. Retrolental fibroplasia: Evidence for a role of the prostaglandin cascade in the pathogenesis of oxygen-induced retinopathy in the newborn beagle. Pediatr Res 1981;15:1293–1302 Schmidt B, Davis P, Moddemann D. Long-term effects of indomethacin prophylaxis in extremely low birth weight infants. N Engl J Med 2001;28:1966–1972 Bandstra ES, Montalvo BM, Goldberg RN. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pediatrics 1988;82:533–542 Yeh TF, Raval D, Pyati S, et al. Retinopathy of prematurity and indomethacin therapy in premature infants with patent ductus arteriosus. Prostaglandins 1983;25:385–391 Darlow BA, Horwood LJ, Clement ERS. Retinopathy of prematurity: Risk factors in a prospective population-based study. Paediatr Perinat Epidemiol 1992;6:62–80 Nandgaonkar BN, Rotschild T, Yuk, Higgins RD. Indomethacin improves oxygen-induced retinopathy in the mouse. Pediatr Res 1999;46:184–188 Beauchamp MH, Martinez-Bermudez AK, Gobeil F Jr, et al. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J Appl Physiol 2001;90:2279–2288 Stuart MJ, Phelps DL, Setty BN. Changes in oxygen tension and effects on cyclooxygenase metabolites: III. Decrease of retinal prostacyclin in kittens exposed to hyperoxia. Pediatrics 1999;82:367–372 Harold J, Schmidt B. Evidence-based neonatology; making a difference beyong discharge from the neonatal nursery. Curr Opin Pediatr 2002;14:165–169 Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatal 2001;6:63–73 Rowlands E. Ionides AC, Chinn S, et al. Reduced incidence of retinopathy of prematurity. Br J Ophthalmol 2001;85:933–935 Console V, Gagliardi L, De Giorgi A, et al. Retinopathy of prematurity and antenatal corticosteroids. The Italian ROP Study Group. Acta Bio-Med Ateneo parm 1997;68(Suppl 1):75–79 Blair BM, O’Halloran HS, Pauly TH, Stevens JL. Decreased incidence of retinopathy of prematurity 1995–1997. J AAPOS 2001;5:118–122